Engineered cystine-knot miniproteins for diagnostic applications

References

• Craik DJ, Daly NL. NMR as a tool for elucidating the structures of circular and knotted proteins. Mol. Biosyst.3(4), 257–265 (2007).
   PubMed Web of Science ®Google Scholar
• Heitz A, Avrutina O, Le-Nguyen D et al. Knottin cyclization: impact on structure and dynamics. BMC Struct. Biol.8, 54 (2008).
   PubMedGoogle Scholar
• Wang CK, Hu SH, Martin JL et al. Combined x-ray and nmr analysis of the stability of the cyclotide cystine knot fold that underpins its insecticidal activity and potential use as drug scaffold. J. Biol. Chem.284(16), 10672–10683 (2009).
   PubMed Web of Science ®Google Scholar
• Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: A new class of agents for imaging integrin expression in living subjects. Cancer Res.69(6), 2435–2442 (2009).
   PubMed Web of Science ®Google Scholar
• Werle M, Kafedjiiski K, Kolmar H, Bernkop-Schnürch A. Evaluation and improvement of the properties of the novel cystine-knot microprotein MCoEETI for oral administration. Int. J. Pharm.332(1–2), 72–79 (2007).
   PubMed Web of Science ®Google Scholar
• Werle M, Schmitz T, Huang HL, Wentzel A, Kolmar H, Bernkop-Schnürch A. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J. Drug Target14(3), 137–146 (2006).
   PubMed Web of Science ®Google Scholar
• Werle M, Kolmar H, Albrecht R, Bernkop-Schnürch A. Characterisation of the barrier caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystine-knot microproteins. Amino Acids35(1), 195–200 (2008).
   PubMed Web of Science ®Google Scholar
• Gelly JC, Gracy J, Kaas Q, Le-Nguyen D, Heitz A, Chiche L. The knottin website and database: a new information system dedicated to the knottin scaffold. Nucleic Acids Res.32(Database issue), D156–159 (2004).
   PubMedGoogle Scholar
• Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin. Pharmacother.9(9), 1575–1583 (2008).
   PubMed Web of Science ®Google Scholar
• Massote PD, Pinheiro AC, Fonseca CG et al. Protective effect of retinal ischemia by blockers of voltage-dependent calcium channels and intracellular calcium stores. Cell Mol. Neurobiol.28(6), 847–856 (2008).
   PubMed Web of Science ®Google Scholar
• Perez-Pinzon MA, Yenari MA, Sun GH, Kunis DM, Steinberg GK. SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J. Neurol. Sci.153(1), 25–31 (1997).
   PubMed Web of Science ®Google Scholar
• Azimi-Zonooz A, Kawa CB, Dowell CD, Olivera BM. Autoradiographic localization of N-type VGCCs in gerbil hippocampus and failure of ω-conotoxin MVIIa to attenuate neuronal injury after transient cerebral ischemia. Brain Res.907(1–2), 61–70 (2001).
   PubMed Web of Science ®Google Scholar
• Chiche L, Heitz A, Gelly JC et al. Squash inhibitors: from structural motifs to macrocyclic knottins. Curr. Protein Pept. Sci.5(5), 341–349 (2004).
   PubMed Web of Science ®Google Scholar
• Craik DJ, Clark RJ, Daly NL. Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins. Expert Opin. Investig. Drugs16(5), 595–604 (2007).
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio C, Molina MA, Fernandez-Salas E et al. Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J. Biol. Chem.273(20), 12370–12377 (1998).
   PubMed Web of Science ®Google Scholar
• Mas JM, Aloy P, Marti-Renom MA et al. Protein similarities beyond disulphide bridge topology. J. Mol. Biol.284(3), 541–548 (1998).
   PubMed Web of Science ®Google Scholar
• Sitja-Arnau M, Molina MA, Blanco-Aparicio C et al. Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Lett.226(2), 169–184 (2005).
   PubMed Web of Science ®Google Scholar
• Bolin KA, Anderson DJ, Trulson JA et al. NMR structure of a minimized human Agouti related protein prepared by total chemical synthesis. FEBS Lett.451(2), 125–131 (1999).
   PubMed Web of Science ®Google Scholar
• Wilczynski AM, Joseph CG, Haskell-Luevano C. Current trends in the structure–activity relationship studies of the endogenous Agouti-related protein (AGRP) melanocortin receptor antagonist. Med. Res. Rev.25(5), 545–556 (2005).
   PubMed Web of Science ®Google Scholar
• McNulty JC, Thompson DA, Bolin KA, Wilken J, Barsh GS, Millhauser GL. High-resolution NMR structure of the chemically-synthesized melanocortin receptor binding domain AGRP(87–132) of the Agouti-related protein. Biochemistry40(51), 15520–15527 (2001).
   PubMed Web of Science ®Google Scholar
• Joppa MA, Gogas KR, Foster AC, Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide AGRP(83–132) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides28(3), 636–642 (2007).
   PubMed Web of Science ®Google Scholar
• Lahti JL, Silverman AP, Cochran JR. Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniprotein. PLoS Comput. Biol.5(9), e1000499 (2009).
   Google Scholar
• Wentzel A, Christmann A, Krätzner R, Kolmar H. Sequence requirements of the GPNG β-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening. J. Biol. Chem.274(30), 21037–21043 (1999).
   PubMed Web of Science ®Google Scholar
• Reiss S, Sieber M, Oberle V et al. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets17(3), 153–157 (2006).
   PubMed Web of Science ®Google Scholar
• Sommerhoff CP, Schaschke N. Mast cell tryptase β as a target in allergic inflammation: an evolving story. Curr. Pharm. Des.13(3), 313–332 (2007).
   PubMed Web of Science ®Google Scholar
• Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D et al. Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis. Chembiochem9(1), 33–37 (2008).
   PubMed Web of Science ®Google Scholar
• Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β. J. Mol. Biol.395(1), 167–175 (2010).
   PubMed Web of Science ®Google Scholar
• Thongyoo P, Bonomelli C, Leatherbarrow RJ, Tate EW. Potent inhibitors of β-tryptase and human leukocyte elastase based on the McoTI-II scaffold. J. Med. Chem.52(20), 6197–6200 (2009).
   PubMed Web of Science ®Google Scholar
• Baggio R, Burgstaller P, Hale SP et al. Identification of epitope-like consensus motifs using mRNA display. J. Mol. Recognit.15(3), 126–134 (2002).
   PubMed Web of Science ®Google Scholar
• Silverman AP, Levin AM, Lahti JL, Cochran JR. Engineered cystine-knot peptides that bind αvβ3 integrin with antibody-like affinities. J. Mol. Biol.385(4), 1064–1075 (2009).
   PubMed Web of Science ®Google Scholar
• Schmoldt HU, Daneschdar M, Kolmar H, Blind M. Microbodies. Methods Mol. Biol.535, 361–372 (2009).
   PubMedGoogle Scholar
• Schmoldt HU, Wentzel A, Becker S, Kolmar H. A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle. Protein Expr. Purif.39(1), 82–89 (2005).
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat. Rev. Cancer2(2), 91–100 (2002).
   PubMed Web of Science ®Google Scholar
• Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell79(7), 1157–1164 (1994).
   PubMed Web of Science ®Google Scholar
• Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium13(2), 113–135 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des.12(22), 2723–2747 (2006).
   PubMed Web of Science ®Google Scholar
• Beer AJ, Haubner R, Sarbia M et al. Positron emission tomography using [18F]galacto-rgd identifies the level of integrin αvβ3 expression in man. Clin. Cancer Res.12(13), 3942–3949 (2006).
   PubMed Web of Science ®Google Scholar
• Haubner R, Weber WA, Beer AJ et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med.2(3), e70 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity. Proteins77(2), 359–369 (2009).
   PubMed Web of Science ®Google Scholar
• Miao Z, Ren G, Liu H et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug. Chem.20(12), 2342–2347 (2009).
   PubMed Web of Science ®Google Scholar
• Li ZB, Cai W, Cao Q et al.64Cu-labeled tetrameric and octameric RGD peptides for small-animal pet of tumor αvβ3 integrin expression. J. Nucl. Med.48(7), 1162–1171 (2007).
   PubMed Web of Science ®Google Scholar
• Liu S. Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem.20(12), 2199–2213 (2009).
   PubMed Web of Science ®Google Scholar
• Kolmar H, Skerra A. Alternative binding proteins get mature: rivalling antibodies. FEBS. J.275(11), 2667 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther.8(10), 2861–2871 (2009).
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev.60(12), 1421–1434 (2008).
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci.29(2), 57–61 (2008).
   PubMed Web of Science ®Google Scholar
• Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J.274(1), 86–95 (2007).
   PubMedGoogle Scholar
• Greenwood KP, Daly NL, Brown DL, Stow JL, Craik DJ. The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis. Int. J. Biochem. Cell Biol.39(12), 2252–2264 (2007).
   PubMed Web of Science ®Google Scholar
• Craik DJ, Daly NL, Waine C. The cystine knot motif in toxins and implications for drug design. Toxicon39(1), 43–60 (2001).
   PubMed Web of Science ®Google Scholar
• Maillere B, Mourier G, Herve M, Cotton J, Leroy S, Menez A. Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon33(4), 475–482 (1995).
   PubMed Web of Science ®Google Scholar
• Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D et al. Trypsin inhibition by macrocyclic and open-chain variants of the squash inhibitor MCoTI-II. Biol. Chem.386(12), 1301–1306 (2005).
   PubMed Web of Science ®Google Scholar